Our findings suggest that the CHA2DS2-VASc score reliably Bemegride predicts poor 30-day stroke outcome, with significantly better predictive ability compared to the CHADS2 score. Flufenamic acid Indeed, on the logistic regression analysis which accounted for blood biomarkers, the presence of AF and a number of clinical/echocardiographic parameters, the model with CHA2DS2-VASc score had an excellent predictive ability for poor short-term stroke outcome. Indeed, even the unadjusted CHA2DS2-VASc score predictive ability was very good, with c-statistic of 0.932. Increasing body of evidence shows that a number of blood biomarkers are significantly associated with various clinical events. For example, a recent large biomarker substudy of the RE-LY trial showed that elevated TnI and NT-proBNP were independently related to increased risks of stroke and mortality and significantly improved risk prediction in AF patients beyond currently used clinical tools. However, the substudy had not investigated the association of biomarkers with stroke outcomes in patients who suffered AIS during follow-up. A recent systematic review of diagnostic and prognostic role of blood biomarkers in AIS highlighted blood glucose and fibrinogen levels as the most consistent predictors of poor functional outcome of stroke. Nonetheless, studies on biomarkers generally suffer from several shortcomings, including relatively small number of patients, variable analytical techniques and interpretation of results, different study population risk profiles, etc. Indeed, a recent study of 270 patients with AIS or TIA, which investigated the prognostic role of 18 blood biomarkers for 90-day functional outcome, found that on adjusted analyses only Interleukin-6 and NT-proBNP were significantly related to poor 90-day outcome, but with no significant improvement in predictive ability when added to age plus NIHSS model. In our study, adjusted TnI and fibrinogen were significantly related to 30-day poor functional outcome of stroke.However, upon adjustment for other biomarkers and clinical/echocardio graphic variables, the CHA2DS2-VASc-F score was no longer significantly associated with 30-day poor outcome.